PERSEUS SENOLYTIX
LIVE

Serial Number

99351616

Owner

SENOTHERAPEUTIX, Inc.

Attorney

Jared L. DuJack

Filing Date

Aug 22, 2025

Add to watchlist:

No watchlists yet
View on USPTO

PERSEUS SENOLYTIX Trademark

Serial Number: 99351616

PERSEUS SENOLYTIX is a trademark filed by SENOTHERAPEUTIX, Inc. on August 22, 2025. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

SENOTHERAPEUTIX, Inc. (2 trademarks)

9511 Collins Avenue #1403
Surfside, FL 33154

Entity Type: 03

Trademark Details

Filing Date

August 22, 2025

Registration Date

Not Registered

Goods & Services

Anti-cancer therapy; Anti-cancer services;Anti-cancer research; Anti-aging therapy; Anti-aging services; Anti-aging research; Pharmaceutical products for the prevention and treatment of cancer and other age-related skin disorders; Development of pharmaceutical preparations and medicines; Research and development of pharmaceuticals for the treatment of cancer and age-related diseases; Testing, inspection, research, or development of pharmaceutical preparations for cancer therapy and age therapy; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, and diagnostics; Peptides for use in cancer and age-related diseases; Peptides for use in skin conditions; Anti-cancer peptides; Anti-aging peptides; Peptides for use in prevention of radiation damage; Peptides for use in treatment of radiation damage; Peptides for use in prevention of radiation related diseases; Peptides for use in treatment of radiation related diseases; Biologic age scoring; Statistical scoring to determine a biologic age score of a patient; Medical services; Medical services, namely, anti-cancer and anti-aging services; Medical services, namely, prevention and treatment of cancer and age-related disorders

Medical research services; Medical research services, namely, anti-cancer and anti-aging services; Medical research services, namely, prevention and treatment of cancer and age-related disorders; Medical advisory services; Medical advisory services, namely, anti-cancer and anti-aging services; Medical advisory services, namely, prevention and treatment of cancer and age-related disorders; Medical testing services; Medical testing services, namely, anti-cancer and anti-aging services; Medical testing services, namely, prevention and treatment of cancer and age-related disorders; Medical services in the field of anti-cancer and anti-aging; Medical services in the field of senescent cells; Medical services in the field of cancer and age-related disorders; Biopsy services; Biopsy services related to cancer; Biopsy services related to biologic age; Biopsy services related to biological age scoring; Biopsy services related to determining a number or percentage of senescent cells; Laboratory services; Laboratory services related to cancer; Laboratory services related to biologic age; Laboratory services related to biological age scoring; Laboratory services related to determining a number or percentage of senescent cells; Non-invasive testing; Non-invasive testing related to cancer; Non-invasive testing related to biologic age; Non-invasive testing related to biological age scoring; Non-invasive testing related to determining a number or percentage of senescent cells; Prevention of cancer; Treatment of cancer; Prevention of radiation damage; Treatment of radiation damage; Prevention of radiation related diseases; Treatment of radiation related diseases

Filing History

APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Apr 20, 2026 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Apr 20, 2026 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jan 22, 2026 GNRN
NON-FINAL ACTION E-MAILED
Jan 22, 2026 GNRT
NON-FINAL ACTION WRITTEN
Jan 22, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 13, 2026 DOCK
NOTICE OF DESIGN SEARCH CODE E-MAILED
Jan 12, 2026 MDSC
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 12, 2026 NWOS
APPLICATION FILING RECEIPT MAILED
Aug 22, 2025 MAFR
NEW APPLICATION ENTERED
Aug 22, 2025 NWAP